Abstract: Elucidation of the immunopathogenesis of psoriasis has led to the discovery of novel biologic agents for the treatment of moderate-to-severe plaque psoriasis. There are currently five biologic agents approved by the US Food and Drug Administration for psoriasis which have proven to be quite efficacious in clinical trials and in post-marketing and clinical experience. As more details are uncovered about the immunologic pathways involved in initiation and maintenance of this disease, there will be an increasing development and marketing of novel therapeutics. It is crucial to understand the immunopathogenesis of psoriasis and the mechanisms of these novel agents in order to to treat the psoriatic population effectively and mitigate disease burden. This article reviews the currently approved biologics for the treatment of psoriasis, with emphasis on efficacy and safety. There are countless therapies currently in the research pipeline, with mechanisms ranging from receptor antagonism to signal transduction pathway inhibition. The initial trials and future studies involving these new agents are also reviewed. As therapeutics escalate through the research pipeline, the management and treatment of psoriasis will likely become more manageable for practitioners and patients.
Introduction
Psoriasis is a chronic immunologically mediated multisystemic disease affecting approximately 125 million people worldwide. 1 The signs and symptoms vary drastically from one patient to another. While patients with limited local disease may respond to topical intervention, others having a large affected body surface area and/or joint disease will require systemic treatment for management. Increased knowledge of the immunopathogenesis of psoriasis has led to improvement in existing treatment options and novel targeted therapies. The development of treatments that modulate key molecules in the pathogenesis of psoriasis has revolutionized management of the disease, leading to a research focus on the development of these novel biologic agents. 2 This article will review currently approved biologic agents as well as promising options in the pipeline for the treatment of psoriasis. It is crucial that providers understand the mechanisms of action of these systemic agents to maximize treatment outcomes.
immune cascade and identifying new disease modulators as potential therapeutic targets 9, 10 ( Figure 1 ). The cell-mediated adaptive immune response is primarily responsible for initiation and maintenance of the disease. 11, 12 While T-helper (Th1) cytokines, ie, interferon-gamma (IFN-g), tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), and IL-12 have long been implicated in the pathogenesis of psoriasis, new research demonstrates the role of Th17 cells in the evolution of the disease. 13, 14 Th17 cells are stimulated by IL-23 and produce many recently identified proinflammatory cytokines, such as IL-17 and IL-22, leading to the recruitment of neutrophils and dysregulation of keratinocytes seen in psoriasis. 15 IFN-g functions synergistically with IL-17 to produce IL-6 and IL-8, which also act to recruit inflammatory cells such as neutrophils. Other studies have shown that Th1 cells can induce the production of Th17 cells through the production of chemokine (C-C motif) ligand-20, a cytokine chemoattractant for dendritic cells, lymphocytes such as Th17 cells, and neutrophils. 16 Further understanding of the role of IL-12 in the production of Th1 cells and its complex interaction within the IL-23/Th17 axis will provide a rationale for unique targeted therapies.
TNF-α, produced by both activated dendritic cells and T cells, including Th1, Th17, and Th22, is often elevated in inflammatory conditions including psoriasis, as evidenced by increased levels found in the serum and blister fluid of patients with the disease. 17 Gene studies have also demonstrated that when TNF-α interacts with IL-17, there is a corresponding increase in gene expression that correlates with the degree of inflammation. 18 Among the newest factors identified in the pathogenesis of psoriasis are IL-22 and IL-20, which share a common receptor complex (IL-22R1). 19 IL-22 effects keratinocyte terminal differentiation, resulting in epidermal hyperplasia and acanthosis, the well known psoriatic phenotype. 20, 21 IL-20, produced by keratinocytes, further perpetuates epidermal hyperplasia, through activation of IL-22R1. 22 Thus, the IL-22R1 receptor appears to be a novel driver of inflammation through positive autoregulatory loops. In clinical studies, elevated serum levels of IL-20 and IL-22 in psoriatic patients correlate with the Psoriasis Assessment Severity Index (PASI). [23] [24] [25] These newly discovered cytokines serve as potential targets for the treatment of psoriasis (Table 1) .
Evaluating efficacy of treatment
Quantifying the severity of psoriasis is important in order to select an appropriate treatment modality and to assess the treatment response subsequently. Clinical trials utilize the PASI to measure improvement of cutaneous lesions objectively; however, this complex system is not practical in busy daily clinical practice. 26 PASI is used in clinical trials because it allows the researcher to score the three major features of psoriasis objectively, ie, redness (erythema), scaling, and thickness (induration), with consideration of the extent of involvement in each body region. A general standard for evaluating superior treatment efficacy is a PASI 75, a 75% improvement from a baseline PASI, and is often considered the primary endpoint of most landmark biologic studies. 27 However, with newer agents having more targeted mechanisms and increasing clinical efficacy compared with previous landmark studies, it is not uncommon to find a PASI 90 or PASI 100 reported in the literature. Other scales used in the evaluation of treatment success include the Physicians Global Assessment (PGA), a measurement of overall disease severity at any given time point for evaluation in a study, and the Dermatology Life Quality Index (DLQI), a questionnaire used for routine clinical assessment of improvement in quality of life following treatment.
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Conventional therapies
Approximately 80% of the psoriatic population has mildto-moderate disease (localized cutaneous manifestations; body surface area # 10%) of which the majority can be successfully managed with topical agents such as corticosteroids, vitamin D3 analogs, vitamin A derivatives, emollients, keratolytics, and/or coal tar. 30, 31 Moderate-to-severe disease with more widespread cutaneous manifestations (body surface area . 10%) and/or nail or joint disease may require phototherapy (ultraviolet B or ultraviolet A radiation) with psoralen, known as photochemotherapy, or systemic agents. 32 Conventional systemic therapies such as MTX, CSA and acitretin can be used in the long term, but often have limitations due to more severe side effects (organ toxicity, skin cancer), lack of sustainable efficacy, and inconvenient administration schedules. 33, 34 Nonetheless, such agents remain a necessity in our therapeutic armamentarium primarily due to their established drug profiles and cost-effectiveness. Furthermore, an unfortunate truth in the US is that most insurance companies require failure of systemic therapy and/or phototherapy prior to approval of a biologic treatment.
Targeted biologic therapy
Elucidation of the immunologic circuits in the pathogenesis of psoriasis has encouraged the development of novel targeted systemic treatment options known as "biologics". By targeting specific pathways in the immunopathogenesis of psoriasis, progression of the disease can be interrupted, resulting in both cutaneous and systemic disease clearance. In some instances, disease clearance may be complete (eg, PASI 100) and long-standing.
There are currently five biologic agents approved by the US Food and Drug Administration for psoriasis, alefacept ( [35] [36] [37] [38] [39] (Table 2) . Newer more targeted agents are in development and in clinical trials.
Another immunosuppressant inhibiting lymphocyte activation and cell migration out of blood vessels into tissues, efalizumab (Raptiva ® , Genentech, South San Francisco, CA), was taken off the market in 2009 when four cases of progressive multifocal leukoencephalopathy (John Cunningham virus brain infection) were reported in plaque psoriasis patients. 42, 43 Other similar biologics, golimumab and certolizumab pegol, have efficacy in psoriasis, but are indicated for other conditions, such as psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. The following is a discussion of the pivotal clinical trials, the efficacy and safety of the currently approved biologics for psoriasis, in addition to the drugs under clinical investigation or development.
Alefacept
Alefacept is a humanized, recombinant, dimeric, fusion protein of lymphocyte function-associated antigen and human immunoglobulin G1 (IgG1), that binds to cluster of differentiation-2(CD2), a cell adhesion molecule on memory T cells, to inhibit lymphocyte activation in psoriatic plaques. 44, 45 Alefacept is administered as a 15 mg intramuscular injection weekly for 12 weeks.
Efficacy
Alefacept was the first biologic agent approved for the treatment of psoriasis after trials demonstrated a statistically significant improvement in clearance rates versus placebo. PASI 75 and 50 were achieved by 33% and 57%, of patients, respectively, who received alefacept 15 mg intramuscularly at weekly intervals for 12 weeks. 46 A maximum improvement from baseline was noted 6 weeks following the last treatment, indicating an interesting post-dosing effect. A single course of alefacept was durable, because a PASI 50 was maintained for an average of 7 months after treatment cessation. 47 Additional treatment courses provided clinical improvement without increasing toxicity for those who did not obtain an adequate response after weekly 15 mg intramuscular injections for 12 weeks (a single course). 48 If multiple treatment courses are anticipated, it is generally recommended to have a gap of 12 weeks for clinical observation between courses. In one randomized trial, up to five courses of intramuscular alefacept were well tolerated. 49 Preliminary data suggest that courses of therapy longer than 12 weeks may enhance efficacy as well, although further research is still necessary. 46 
Safety
Alefacept is currently the only approved T cell modulator for the treatment of psoriasis. Efalizumab was the only other agent in a similar class, but was removed from the market in 2009 after it was associated with demyelinating central nervous disease as described above. 50 associated with demyelinating disease and is generally well tolerated.
Alefacept induces dose-dependent reductions in T lymphocytes, therefore reduction in the CD4
+ T cell count is a potential safety concern. CD4 + T cell counts must be monitored before initiation of therapy and every 2 weeks throughout the 12-week treatment course. Therapy should be halted if the CD4 + T cell count falls below 250 cells/µL and discontinued completely if the count remains below this threshold for one month. 35 In clinical trials, chills within the first 24 hours of the initial treatment dose were reported in 10% of patients versus 1% of those treated with placebo. 47 Elevations in liver enzymes have been reported in the drug-treated groups, although there has been no report of clinical significance in these elevations. 46, 47 The observational AWARE (Amevive Wisdom Acquired from Real-World Evidence) trial is a multicenter Phase IV Canadian registry of psoriasis patients treated with alefacept which has further substantiated previous conclusions that alefacept is both efficacious and safe, with few serious adverse events reported and no requirement to discontinue the drug for persistently low CD4 + T cell counts. 51 
TNF-α inhibitors Etanercept
Etanercept is a recombinant, human TNF-α receptor protein linked to the fragment crystallizable region of human IgG1, which inhibits both soluble and membrane-bound TNF-α. 36, 52 Etanercept has shown extensive long-term benefit in patients with moderate-to-severe psoriasis, with clinical trials reporting PASI 75 scores up to 49%. A randomized Phase III trial demonstrated superior efficacy of three dosing regimens, with a PASI 75 (after 12 weeks of treatment) achieved in 4%, 14%, 34%, and 49% of patients in the placebo, lowdose, medium-dose, and high-dose groups, respectively.
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The CRYSTEL (Clinical Randomized Year-Long Study Assessing the Safety and Efficacy of Etanercept in Psoriasis) study, a 54-week open-label investigation of patients with moderate-to-severe plaque psoriasis, demonstrated that both continuous and intermittent etanercept treatment regimens improved PASI scores and quality of life. 55, 56 Patients in the continuous group received 25 mg of subcutaneous etanercept twice weekly for 54 weeks, while the intermittent group received etanercept 50 mg subcutaneously twice weekly for a maximum of 12 weeks or until a PGA # 2 (mild or better) was reached. When patients experienced treatment relapse (PGA $ 3), etanercept was resumed at 25 mg subcutaneously twice weekly until an adequate response (PGA # 2) was again achieved. Both the continuous and intermittent treatment groups had significant improvement in PASI scores from baseline at week 54 (68% and 59%, respectively) indicating that those who restart treatment can still achieve a clinical response.
The sustainability of clinical efficacy has also been established, utilizing PGA and DLQI scores over a period of up to 4 years. 57 At 48 months, 75.9% of patients enrolled in one of the two major Phase II trials who received subcutaneous doses of either 25 mg twice weekly, 50 mg weekly, or 50 mg twice weekly maintained a DLQI response of greater than five-point improvement from baseline and 27.8% maintained a PGA response of clear to almost clear. There were no rates of tuberculosis or lymphoma reported during the study period, and serious adverse events and infections occurred rarely, at a rate of 0.8 events per 100 patient-years and 0.9 events per 100 patient-years, respectively. Thus, the authors concluded that etanercept has long-term benefits and that dose-adjusted rates of adverse events and infections were similar to those in patients receiving placebo.
Infliximab
Infliximab, an intravenously administered chimeric IgG1 antibody made from both human and murine sequences, neutralizes TNF-α by binding to both the soluble and transmembrane forms. 58 In a multicenter, double-blind, placebo-controlled Phase II trial, 249 patients with chronic plaque psoriasis who had failed previous treatments were enrolled to receive infliximab. 59 Patients received placebo or infliximab 3 mg/kg or 5 mg/kg intravenously at 0, 2, and 6 weeks. At week 10, PASI 75 was achieved by 6%, 72%, and 88% of patients in the placebo, 3 mg/kg, and 5 mg/kg groups, respectively. Rapid improvement occurred soon after the first infusion, with a clinical response evident as early as week 2 of treatment.
The Phase III EXPRESS (European Infliximab for Psoriasis [Remicade] Efficacy and Safety Study) evaluated the efficacy and safety of infliximab for induction and maintenance therapy or induction therapy followed by multiple regimens of maintenance therapy. 60, 61 Significant results from the initial EXPRESS I trial in which the treatment group received 5 mg/kg intravenous induction at 0, 2, and 6 weeks followed by maintenance therapy every 8 weeks for 46 weeks showed that 61% and 45% of treated patients achieved PASI 75 and PASI 90, respectively, at 50 weeks. Nail psoriasis was also shown to improve significantly in the treatment group. The EXPRESS II trial evaluated the efficacy of continuous versus intermittent maintenance therapy following infliximab induction using both the 3 mg/kg and 5 mg/kg dosing regimens. Greater durability of the treatment response was achieved with continuous maintenance therapy. There was a dose-dependent response, with more patients achieving a PASI 75 in the 5 mg/kg versus the 3 mg/kg treatment group (75.5% versus 70.3%) compared with the placebo response of 1.9%. 61 Neutralizing human antichimeric antibodies have been reported to occur in approximately 16% of patients treated with infliximab. 62 These are neutralizing antibodies against the murine portion of infliximab and are thought to be responsible for the loss of sustainable treatment efficacy seen in patients treated long-term with infliximab. In contrast, antibodies to etanercept occur less often (approximately 3%) and are thought to be non-neutralizing. 63 Patients producing antibodies may experience decreased treatment efficacy with the cause being currently undefined. The presence of these antibodies is not only associated with a reduction in response to infliximab, but is also associated with the development of infusion reactions. 64, 65 The combination of infliximab with low-dose methotrexate can decrease human antichimeric antibody formation and result in increased overall efficacy, decreased chance of loss of treatment efficacy, and decreased rates of infusion reactions. 66 
Adalimumab
Adalimumab, the first fully human IgG1 monoclonal antibody to TNF-α, inhibits binding of the TNF-α molecule to its receptor. 38 Adalimumab is administered 40 mg subcutaneously every other week after the initial 80 mg subcutaneous loading dose.
A landmark randomized trial compared adalimumab administered by subcutaneous injection (40 mg every other week or 40 mg weekly) versus placebo in the treatment of psoriasis and found that after 2 weeks, more patients treated with adalimumab every other week or weekly achieved at least a 75% improvement (53% and 80%, respectively) versus 4% with placebo. 67 In an open-label extension of the study, improvements were sustained for 60 weeks.
In the milestone Phase III REVEAL (The Randomized controlled EValuation of adalimumab Every other week in moderate to severe psoriasis trial) trial, over 1000 patients were randomized to receive adalimumab 40 mg subcutaneously every other week (after the initial 80 mg subcutaneous loading dose) or placebo for 15 weeks. 68 At week 16, 71% versus 7% achieved PASI 75 in the treatment group and placebo groups, respectively. Patients in the treatment group, who had achieved at least a PASI 75 at week 16, received open-label adalimumab from weeks 17 to 31. Patients with a PASI 75 response after 33 weeks of continuous therapy were rerandomized to either adalimumab or placebo in order to evaluate loss of adequate response (defined as a PASI score that was less than a 50% reduction relative to the week 0 baseline score and at least a 6-point increase in PASI score from week 33). The percentage of patients who lost an adequate response was significantly greater for those receiving placebo than for those receiving treatment (28% versus 5%).
In a recently published open-label extension of the REVEAL trial, patients received adalimumab for a total of 3 years. 69 Those who initially sustained PASI 75 during REVEAL maintained their improvement after both 100 and 160 weeks of continuous therapy, and a PASI 75 was achieved by 83% and 76% of patients, respectively, with no difference in the safety profile from the original trial. Adalimumab was also demonstrated to be an effective treatment for Japanese patients with psoriasis, with rapid response rates (as early as week 4) and PASI 75 achieved by 62.8% versus 4.3% of patients when compared with placebo, as evidenced by a recent trial. Since this antibody is completely humanized, it has been suggested that antibodies against the drug are less likely. Studies have substantiated this hypothesis as only 8% of patients have evidence of antibody formation. However, the presence of these antibodies may explain a resultant loss of clinical response in some patients after long-term use.
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Safety TNF-α antagonists have been utilized in the treatment of rheumatoid arthritis and inflammatory bowel disease for over 10 years, so safety data has been demonstrated and justified by use of these agents in diseases other than psoriasis. However, data from the psoriasis trials confirm the established drug profiles. Major tuberculosis, are a noted risk, and all three agents have a black box warning required by the Food and Drug Administration concerning the development of serious infections, including tuberculosis and disseminated fungal diseases, such as coccidioides and histoplasmosis. 74, 75 Opportunistic infections have been reported, but many of the patients were treated concomitantly with other immunosuppressive agents, which is typical of treatment for inflammatory bowel disease or rheumatoid arthritis, but far less common in the treatment of psoriasis, possibly limiting the potential for infection in this population. [76] [77] [78] The Food and Drug Administration recently requested that the etanercept boxed warning and prescribing information be updated to include legionella, listeria, and blastomycosis as potential infectious risks. 79 Treatment may slightly increase the risk of melanocytic and nonmelanocytic skin cancers, including squamous cell carcinoma, basal cell carcinoma, and cutaneous T cell lymphoma. 80, 81 A comprehensive observational study reported that patients receiving TNF-α inhibitors for rheumatoid arthritis had a 1.5 odds ratio for nonmelanocytic skin cancers and a trend towards increased risk of melanoma (odds ratio 2.3). 82 The increased risk of lymphoma and other solid organ cancers is less clear. Studies have produced conflicting reports, have been underpowered to assess the risk of rare events, and have been tainted by the fact that patients with psoriatic disease are at an intrinsic increased risk of developing lymphoma. [83] [84] [85] Other reported events include development or worsening of both central and peripheral demyelinating diseases, druginduced lupus-like syndromes, and worsening of congestive heart failure. Despite these safety concerns, meta-analyses of published trials conclude that the benefit of successful treatment is greater than the risk of serious events or toxicity. 86 
Ustekinumab
Ustekinumab is a novel, fully humanized IgG1 monoclonal antibody specific for the common p40 subunit of both IL-12 and IL-23 which prevents interaction with their receptor and inhibits T cell differentiation. Administered as a subcutaneous injection, ustekinumab is dosed by weight at 45 mg (weight # 100 kg) or 90 mg (weight . 100 kg), and is administered every 12 weeks after the initial two doses spaced four weeks apart. 39 
Efficacy
Initial Phase I data revealed that a single dose was well tolerated and resulted in a significant clinical response. 87 Four dosing regimens were evaluated in a double-blind, placebo-controlled Phase II trial and concluded that each therapeutic regimen had efficacy over placebo, with a striking clinical response at 12 weeks and improvement in quality of life as early as 2 weeks. 88 The major Phase III trials comparing ustekinumab with either placebo in PHOENIX (Phase 3, Multicenter, Randomized, Double-blind, Placebocontrolled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with moderate to Severe Plaque-type Psoriasis followed by Long-term extension) I/II or etanercept in ACCEPT (Active Comparator CNTO1275/ Enbrel Psoriasis Trial) has confirmed superior safety and efficacy.
The PHOENIX trials assessed both short-term and long-term efficacy and safety in approximately 2000 patients. The studies consisted of three phases, ie, random assignment, crossover at week 12, and rerandomization. In rerandomization, responders received either placebo or maintenance of active treatment (PHOENIX I) and the partial responders received drug treatment every 8 weeks (dose intensification) or continued treatment every 12 weeks (PHOENIX II). 89, 90 A PASI 75 response was achieved by up to 67.1% of patients at week 12 in the higher-dosed group during PHOENIX I. The maximum response was achieved by week 24 for both dosing groups. A PASI 75 response was better maintained to at least one year in those receiving maintenance ustekinumab than in those withdrawn from treatment at week 40. 89 Patients reported that quality of life was significantly improved when compared with placebo, indicated by a separate analysis of this trial. 91 PHOENIX II further established the effect of ustekinumab, when patients achieving a PASI 75 at week 28 and continued on maintenance treatment until week 52 sustained their clinical response. At week 28, partial responders (defined as those achieving a PASI score between 50 and 75) were randomly assigned to continue 12-weekly dosing or to escalate to 8-weekly dosing. Interestingly, more frequent dosing did not enhance response rates at one year in patients receiving 45 mg, but did enhance improvement rates in those receiving 90 mg. Independent predictors of a partial response included treatment with the lower dose, higher body weight, failure to respond to at least one biologic agent, longer duration of psoriasis, and a history of psoriatic arthritis. Notably, ustekinumab antibodies were present in 13% of partial responders, compared with only 2.0% of complete responders, defined as those achieving a PASI 75. 90 The pivotal ACCEPT trial demonstrated superior efficacy of ustekinumab (45 mg groups, respectively. Additionally, no significant safety differences were found between the groups. 92 
Safety
The long-term effects of ustekinumab remain unknown, and much information will stem from post-marketing surveillance and additional long-term studies. Cumulative safety experience was analyzed through the pooling of safety data from the four Phase II and III psoriasis trials gathered over 3 years of treatment. Rates of serious infection during the placebo-controlled periods were similar between placebo (1.70) and ustekinumab 90 mg (1.97) groups, yet lower in the ustekinumab 45 mg group (0.49). 93 The rates of nonmelanoma skin cancer and other malignancies were consistent with the expected incidence in the general US population based on the Surveillance, Epidemiology, and End Results (SEER) database. 94 A major concern is the disproportionate number of major adverse cardiac events seen in the first 12 weeks of the Phase II trial. 88 Ultimately, it was determined that a high proportion of patients recruited into the trials had significant cardiovascular risk factors, such as obesity, smoking, high blood pressure, and diabetes. [95] [96] [97] However, significant concern about this issue prompted a retraction of the US Food and Drug Administration approval for briakinumab (another humanized monoclonal antibody to the p40 subunit of IL-12 and IL-23), and clinical trials were stopped in the treatment of psoriasis.
A meta-analysis of randomized, placebo-controlled, double-blind, monotherapy studies evaluated cardiovascular outcomes for the anti-IL-12/23 agents (ustekinumab and briakinumab) and anti-TNF-α agents (adalimumab, etanercept, and infliximab). The primary outcome was a major adverse cardiac event during the placebo-controlled portion of the study. 98 There were more major adverse cardiac events reported in patients who received active treatment with anti-IL-12/23 inhibitors than in the placebo group (10/3179 patients versus 0/1474 patients). These results lack statistical significance, suggesting that an increase in major adverse cardiac events during the early weeks of treatment may be due to an inherent disease risk in the psoriatic patient population.
Monitoring of patients receiving biologic therapy
Given that there are adverse events associated with biologic therapy, it is necessary to prescreen patients prior to initiation and to continue monitoring patients during and after treatment (Table 3) . Various agencies, such as the Food and Drug Administration and Centers for Disease Control, in addition to key consensus statements, have provided recommendations regarding monitoring. 99, 100 Prior to initiation, it is recommended to obtain a complete medical history and physical examination, as well as baseline laboratory values. 101 All recommendations on monitoring protocol stem from reported adverse events, and differ depending on the mechanism of action of the agent concerned (Table 4) .
New drugs in pipeline: from small molecules to receptors
The list of agents that are under development for psoriasis continues to expand as further understanding of the pathogenesis of the disease is elucidated. Drugs in the research pipeline include oral, injectable, and topical agents that inhibit ILs, IL receptors, or molecules involved in immunologic signaling cascades. Many of these drugs are in Phase II and III trials, while others are just approaching human administration in Phase I trials.
Monoclonal antibodies Secukinumab
Secukinumab (AIN-457, Novartis, Chicago, IL) is a fully humanized IgG monoclonal antibody to IL-17A, an inflammatory mediator implicated in autoimmune diseases, including psoriasis. Phase III trials are currently investigating efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis, and rheumatoid arthritis. [103] [104] [105] Initial Phase Table 3 Recommendations for monitoring patients on biological therapy [99] [100] [101] [102] • CBC and CMP at baseline and every 3-6 months • Hepatitis and Hiv screen at baseline if risk factors present or if symptoms develop • LFTs before each infliximab infusion or with signs and symptoms of liver injury • CD4 + T cell count at baseline and every 2 weeks for alefacept
• Full body screen for skin cancer and signs of systemic disease (lymphoma) every 3-6 months • Standard vaccinations prior to initiation of biologic therapy • Injected influenza*, pneumococcal, and/or hepatitis vaccination to high-risk individuals prior to initiation of biologic therapy • Avoidance of live and/or live-attenuated vaccinations while on biological therapy (MMR, nasal spray influenza, varicella, herpes zoster, yellow fever, rabies, BCG, typhoid) II trials and preliminary reports reveal improved PASI scores after a single intravenous administration when compared with placebo, with similar adverse events in the treatment and placebo group. 106 After monthly subcutaneous administration of 150 mg, PASI 75 at 12 weeks was achieved by 81% of study participants. 107 Ongoing Phase III trials in patients with psoriasis are studying the long-term safety and efficacy of AIN-457, in addition to dosing regimens (150 mg versus 300 mg subcutaneous versus placebo) for both maintenance and for therapy following relapse.
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AMG-827
AMG-827 (Amgen) is a fully humanized antibody that selectively targets the human IL-17 receptor and is currently in Phase II trials for psoriasis and rheumatoid arthritis. 110, 111 Following a single intravenous injection (700 mg), skin biopsies from treated subjects showed variant cytokine gene expression. Studies demonstrated a decrease in genes implicated in psoriasis, especially those associated with epidermal thickness and markers of cellular proliferation. Clinical response was also significant, as seven of eight (87.5%) treated patients achieved a PASI 75 or greater at week 6.
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LY2439821
LY2439821 (Eli Lilly, Indianapolis, IA) is a humanized IgG4 monoclonal antibody that neutralizes IL-17 with high specificity, and was found to be efficacious for patients with rheumatoid arthritis when compared with placebo in a randomized Phase I proof-of-concept study. 113 A Phase II study evaluating the efficacy of subcutaneous administration at various doses (10-150 mg) for a total of six doses (0, 2, 4, 8, 12, and 16 weeks) for patients with moderate-to-severe plaque psoriasis is still ongoing. 114 A Phase III trial evaluating efficacy and safety following an induction dosing period (80 mg subcutaneous twice at week 0) with a subsequent randomized maintenance dose period and long-term extension follow-up period began recruiting patients in November 2011 with an estimated primary completion date of April 2014. 115 
Fezakinumab
Fezakinumab (ILV-094, Pfizer Inc, New York, NY) is a monoclonal antibody targeting IL-22, a cytokine that has shown to affect keratinocytes by inducing hyperplasia and acanthosis. 21 Phase II trials have been completed for rheumatoid arthritis and a Phase I trial investigating both subcutaneous and intravenous administration at 2-week intervals has been completed without published results.
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Oral anti-inflammatory agents Apremilast Apremilast (CC-10004, Celgene, Summit, NJ) is a phosphodiesterase-4 inhibitor shown to decrease TNF-α production. Apremilast reduces epidermal thickness and reduced expression of TNF-α in a murine model of psoriasis. 118 A larger Phase IIb trial randomized 352 patients with moderate-to-severe plaque psoriasis to receive either apremilast (10 mg, 20 mg, and 30 mg) orally twice daily or placebo. The study showed that 41%, 29%, and 11% of patients in the 30 mg 20 mg, and 10 mg treatment arms, respectively, achieved a PASI 75 at 16 weeks compared with 6% of placebo-treated patients. 119 Phase III trials are currently underway evaluating the efficacy of 30 mg twice a day with subsequent retreatment at the same dose following discontinuation and relapse (loss of PASI 50) as well for psoriatic arthritis. 120, 121 voclosporin Voclosporin (ISA-247, Isotechnika Pharma, Edmonton, Canada) is similar to cyclosporine in that it is also a calcineurin inhibitor; however, this new drug differs by having an amino acid modification resulting in increased binding to calcineurin and faster elimination of metabolites. In turn, it appears the overall effect is a greater physiologic response with fewer adverse events, especially in regards to renal toxicity. 122, 123 Initial Phase II studies showed that orally administered voclosporin was superior to placebo after 12 weeks of treatment, with a PASI 75 achieved by 66.7% of drug-treated patients versus none of the placebo-treated patients. 122, 124 Trials demonstrated that plasma voclosporin concentrations correlated with the clinical response, suggesting that drug efficacy may be accomplished by monitoring blood levels, which is a limitation with the other calcineurin inhibitors. Quality of life measures, including the DLQI and the Psoriasis Disability Index, a questionnaire investigating the level of harm resulting from psoriasis, were shown to improve following treatment. 125 Unlike other calcineurin inhibitors, voclosporin does not result in permanent renal toxicity or increase blood pressure and lipid levels following treatment; however, creatinine levels increase at higher treatment doses. ESSENCE (the European and Canadian pivotal Phase 3 psoriasis trial) was the first study to compare the efficacy of cyclosporine and voclosporin directly where patients were randomized to receive voclosporin 0.4 mg/kg orally twice daily, cyclosporine 1.5 mg/kg orally twice daily, or placebo. 126 At 12 weeks, 35% of patients achieved a score of clear or almost clear on static PGA score compared with 6% of those on placebo. Additionally, a PASI 75 was achieved by 43% and 26% of voclosporin-treated patients at 12 and 60 weeks, respectively. Voclosporin had significant improvements when compared with cyclosporine in rates of hypertension and hyperlipidemia, and had fewer reported adverse events.
CF-101
CF-101 (Can-Fite, Waltham, MA) is an adenosine A3 receptor inhibitor that also inhibits the production of inflammatory cytokines, such as TNF-α and autoreactive T cells, and also induces apoptosis of inflammatory cells. 127 Prior to trials in psoriasis, Phase II trials for rheumatoid arthritis and keratoconjunctivitis sicca established the drug to be safe and well tolerated. Phase II trials have demonstrated improvement in mean PASI scores from baseline after 12 weeks of 2 mg twice daily oral dosing, with 35.5% of subjects achieving PASI 50 and 23.5% of patients achieving a PGA score of 0 or 1. 128 Although Phase III trials for psoriasis have not yet been completed, the existing information supports the safety and efficacy of CF-101 in patients with moderate to severe psoriasis. 129 Currently, Phase III trials for dry eye and Phase II trials for increased intraocular pressure and knee osteoarthritis are ongoing.
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Sotrastaurin Sotrastaurin (AEB-071, Novartis AG, Basel, Switzerland) is an inhibitor of numerous subtypes of protein kinase C, which ultimately leads to the prevention of early T cell activation. 133 Sotrastaurin inhibits T cell proliferation in a dose-dependent manner and reduces the production of key cytokines, including IL-17, IFN-g, IL-2, and TNF-α. 134 When treatment groups received 25, 100, 200, or 300 mg orally twice daily a mean reduction in PASI scores was achieved during the initial 2 weeks of treatment. The average decrease of PASI scores over baseline was 69% for the 300 mg twice daily cohort, which was the highest dosage tested. The majority of patients in this treatment group (66.7%) achieved a PASI 75. 135 However, many patients in the treated groups relapsed during the 2-week treatment-free follow-up period and only patients in the highest dose group still showed sustained clinical improvement. The treatment was well tolerated, with the incidence of adverse events being similar in the treatment and placebo groups; however, larger clinical studies are necessary to evaluate the true safety of sotrastaurin in addition to its efficacy. Sotrastaurin is currently in Phase II trials for psoriasis, ulcerative colitis, and renal transplant rejection, in addition to Phase I trials for metastatic uveal melanoma.
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BMS-582949
BMS-582949 (Bristol-Myers Squibb, New York, NY) is a p38 kinase inhibitor and is currently in Phase II trials for psoriasis. The p38 membrane-associated protein kinases are a family of serine/threonine protein kinases that play an important role in the cellular response to external stimuli, including stress signals. TNF-α stimulation and production has been linked to signals originating from p38 membraneassociated protein kinases. 140 Preclinical models have suggested that inhibition of the p38 membrane-associated protein kinase pathway can reduce skin inflammation in animals. 141 Phase II trials for psoriasis, rheumatoid arthritis, and atherosclerosis have been completed, with no relevant data published in the peer-reviewed journals at the time of writing of this article.
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Janus kinase inhibitors Tofacitinib
One of the emerging new targets in the treatment of psoriasis is the Janus kinase (JAK) pathway, which is comprised of cytoplasmic tyrosine kinase proteins that phosphorylate and activate the signal transducer and activator of transcription transduction pathway associated with production of Th17 cells. 145 As a selective inhibitor of JAK3, tofacitinib (CP-690550, Pfizer Inc, New York, NY) suppresses signal transduction of ILs, including IL-2, IL-7, IL-9, IL-15, and IL-21. Results from a Phase II trial which randomized 197 subjects to receive 2 mg, 5 mg, 15 mg of oral tofacitinib or placebo twice daily were presented at the annual meeting of the European Academy of Dermatology and Venereology held in October 2010 at Gothenburg, Sweden. A PASI 75 was achieved by 25%, 40.8%, and 66.7% of drug-treated patients compared with 2.0% of placebo-treated patients.
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Although the adverse events in this study were comparable with those reported for other biologic agents, the Phase III trial in rheumatoid arthritis has reported four deaths, none of which have not been linked with tofacitinib. Ongoing Phase III trials are evaluating the safety of tofacitinib in the psoriatic population. 148 Other selective JAK3 inhibitors are in the initial phases of development for psoriasis and rheumatoid arthritis, although no published data are currently available. 149 
Ruxolitinib
Ruxolitinib (INCB018424, Incyte Corporation, Wilmington, DE) is a topically administered inhibitor of the JAK1 and JAK2 molecule, and was shown to reduce cutaneous edema, lymphocyte infiltration, keratinocyte proliferation, acanthosis, and IL-22 in a murine model of cutaneous inflammation. 150 The drug is currently in Phase II development for psoriasis, myelofibrosis, acute leukemia, polycythemia vera, and essential thrombocytosis.
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Conclusion
Immunomodulators including biologics have changed the therapeutic management of psoriasis, providing physicians with the opportunity to directly target the known key mediators in the pathogenesis of this disease. The demand for novel and improved therapies continues to grow, and can only be met by continued research. New biologic agents will continue to target more specific, smaller molecules involved in the inflammatory cascade to help limit side effects while maximizing efficacy. The previous advances made in biological therapy for the treatment of psoriasis have laid the foundation for drugs in the research pipeline allowing us to focus our treatment considerations dramatically.
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